VOGLIBOSE 0.2 MG + GLIMEPIRIDE 2 MG + METFORMIN HYDROCHLORIDE 500 MG SR

STRIP of 10 TAB.

Rx Prescription Required

VOGLIBOSE 0.2 MG + GLIMEPIRIDE 2 MG + METFORMIN HYDROCHLORIDE 500 MG SR

Manufacturer : BAJAJ FORMULATIONSIn StockProduct Code : GMP0309MRP : ₹ 103.00 (Inclusive of all taxes)₹ 50.0051.46% Off Quantity : Add Request

Product Details

VOGLIBOSE 0.2 MG + GLIMEPIRIDE 2 MG + METFORMIN HYDROCHLORIDE 500 MG SR

Introduction :

The combination of Voglibose 0.2 mg, Glimepiride 2 mg, and Metformin Hydrochloride 500 mg SR is a medication used for the management of type 2 diabetes.

Indication :

The combination is indicated for the treatment of type 2 diabetes when diet and exercise alone do not provide adequate glycemic control.

Administration :

The dosage may vary, and it should be determined by a healthcare professional based on the patients individual needs and response to treatment.

Storage :

Store at a controlled room temperature between 15 and 30 degrees C (59 and 86 degrees F); protect from light and moisture

Side Effects :

- Common side effects may include gastrointestinal symptoms such as nausea, diarrhea, and abdominal discomfort. Hypoglycemia (low blood sugar) is a potential side effect, particularly with Glimepiride.

Contraindications :

Its important to monitor for signs of hypoglycemia and adjust the dosage accordingly. The combination is contraindicated in patients with hypersensitivity to any of its components.

References :

https://www.centaurpharma.com/downloads/Glimitab-MV2018.pdf Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149. doi:10.2337/dc14-2441.

Mechanism of Action :

The mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Metformin improves glucose tolerance in patients with type-2 diabetes (NIDDM), lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Voglibose (Alpha-glucosidase inhibitors) are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates: specifically alpha-glucosidase enzymes in the brush border of the small intestines

Disclaimer

At Genericart, our primary goal is to provide information that is thoroughly reviewed, accurate, and reliable. However, it is important to note that the content provided here should not be considered a substitute for professional medical advice. The information presented on our platform is intended for educational purposes only and may not cover all aspects of specific health conditions, medications, potential side effects, drug interactions, warnings, or alerts. We strongly encourage consulting with a qualified healthcare professional for advice and guidance regarding their health concerns and medication needs.